Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma

PHASE3CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

May 23, 2019

Primary Completion Date

April 26, 2022

Study Completion Date

April 26, 2022

Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
DRUG

Gemcitabine

1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.

DRUG

Paclitaxel

80 mg/m² in IV infusion over 60 minutes at Day 1, 8 and 15 followed by 1 week of rest.

Trial Locations (26)

75011

Hôpital Saint-Louis, Paris

75014

Institut Mutualiste Montsouris, Paris

Unknown

CH de Bayeux, Bayeux

CH Simone Veil, Beauvais

CHU Jean Minjoz, Besançon

Hôpital Duchenne, Boulogne-sur-Mer

CH du Cotentin, Cherbourg

Centre Georges François Leclerc, Dijon

Centre Léon Bérard, Lyon

Hospices civils de Lyon, Lyon

CHU La Timone, Marseille

Hôpital Européen de Marseille, Marseille

Hôpital Saint-Joseph, Marseille

Institut Paoli Calmettes, Marseille

Hôpital Nord Franche Comté, Montbéliard

Centre Antoine Lacassagne, Nice

Hôpital Pitié-Salpétrière, Paris

Institut Godinot, Reims

Centre Eugène Marquis, Rennes

CHU Rouen, Rouen

Institut Curie, Saint-Cloud

CHU de Saint-Etienne, Saint-Etienne

Institut de Cancérologie de l'Ouest, Saint-Herblain

Hôpital Broussais, St-Malo

Hôpital Trousseau, Tours

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

UNICANCER

OTHER

NCT03943667 - Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma | Biotech Hunter | Biotech Hunter